LOGIN  |  REGISTER
Compass Therapeutics

Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

April 16, 2025 | Last Trade: US$1.51 0.05 3.42

MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (international), conference ID: 8141169.

A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2025.

About Accuray

Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor Contact
Aman Patel, CFA
Investor Relations, ICR Healthcare
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page